"上市公司"） 证券代码：002793 股票简称：罗欣药业 公告编号：2025-047 罗欣药业集团股份有限公司 关于持股 5%以上股东的一致行动人减持股份预披露公告 本公司持股 5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管 理有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"、 "本公司"、 持股 5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管理有限公司 （曾用名：温岭市大任投资管理有限公司、盐城大任企业管理有限公司，以下简 称"大任管理"或"大任投资"）合计持有公司股份 131,620,846 股（占剔除本 公司回购专用账户 7,808,358 股后的总股本比例 12.19%）；其中，方秀宝持有 方东晖持有 20,884,500 股（占剔除本公司回购专用账户 7,808,358 股后的总股本 比例 1.93%）；大任管理单独持有公司股份 10,442,080 股（占剔除本公司回购专 用账户 7,808,358 股后的总股本 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-047 罗欣药业集团股份有限公司 关于持股 5%以上股东的一致行动人减持股份预披露公告 本公司持股 5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管 理有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"、"本公司"、"上市公司"） 持股 5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管理有限公司 （曾用名：温岭市大任投资管理有限公司、盐城大任企业管理有限公司，以下简 称"大任管理"或"大任投资"）合计持有公司股份 131,620,846 股（占剔除本 公司回购专用账户 7,808,358 股后的总股本比例 12.19%）；其中，方秀宝持有 100,294,266股（占剔除本公司回购专用账户7,808,358股后的总股本比例9.29%）； 方东晖持有 20,884,500 股（占剔除本公司回购专用账户 7,808,358 股后的总股本 比例 1.93%）；大任管理单独持有 ...

罗欣药业（002793）公告，持股5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管理有限 公司合计持有公司股份1.32亿股，占剔除回购专用账户股份后的总股本比例12.19%。大任管理计划通过 集中竞价或大宗交易方式减持不超过1044.21万股，占公司总股本比例0.96%，减持期间为公告披露日起 15个交易日后的三个月内。 ...

Market Performance - A-shares showed strong momentum with major indices rising, Shanghai Composite Index surpassed 3400 points, and ChiNext Index increased over 1% [1] - Hong Kong stocks also performed well, with the Hang Seng Index rising over 1% and returning above 24000 points, while the Hang Seng Tech Index surged nearly 3% [1] - Total market turnover reached approximately 1.31 trillion yuan, an increase of 135.5 billion yuan from the previous trading day [1] Innovative Drug Sector - The innovative drug concept stocks experienced significant gains, with the innovative drug index rising over 4% [2] - Notable stocks included Hai Chen Pharmaceutical, Rui Zhi Pharmaceutical, and others, with nearly 15 related stocks hitting the daily limit or rising over 10% [2] - Since mid-May, innovative drug stocks have shown strong performance, with some stocks like Lianhua Technology increasing nearly 115% in the last nine trading days [2] Industry Developments - The 2025 American Society of Clinical Oncology (ASCO) annual meeting highlighted the competitiveness of Chinese pharmaceutical companies in new drug development [3] - Financial policies introduced since May 7 aim to stabilize market expectations, with a focus on supporting leading pharmaceutical companies with strong dividends [3] Rare Earth Sector - The rare earth sector became active, with the rare earth permanent magnet concept index rising 3.45% [4] - The demand for medium and heavy rare earths is increasing due to the development of industries like robotics and electric vehicles [4] - Supply tightening and policy changes have led to a recovery in rare earth prices, with expectations for continued moderate price increases [5] Elderly Care Robotics - The elderly care robotics sector showed strong performance, with the humanoid robot concept index rising 0.76% [7] - The Ministry of Industry and Information Technology and the Ministry of Civil Affairs announced a pilot program for intelligent elderly care service robots from 2025 to 2027 [7] - The report emphasized the investment value of the robotics sector, highlighting various types of intelligent elderly care robots that cater to different needs [8]

Group 1 - The A-share market's innovative drug concept stocks have shown strong performance, with the innovative drug sector index reaching a historical high [1] - Notable individual stock performances include Xinghao Pharmaceutical rising over 25%, RuiZhi Pharmaceutical hitting a 20% limit up, and Changshan Pharmaceutical reaching a historical high [1][2] - The overall pharmaceutical sector has experienced a prolonged adjustment period, resulting in low valuations and underweight public holdings, indicating potential for recovery and structural opportunities [2] Group 2 - Specific stock performances include: - Xinghao Pharmaceutical: 25.82% increase, market cap of 3.045 billion [2] - RuiZhi Pharmaceutical: 19.98% increase, market cap of 5.801 billion [2] - Changshan Pharmaceutical: 19.97% increase, market cap of 47.9 billion [2] - Shutaishen: 12.12% increase, market cap of 15.6 billion [2] - The report from China Galaxy Securities suggests that the pharmaceutical market is expected to see continuous recovery and that innovative drug companies will benefit from policy support and improved payment conditions by 2025 [2]

Economic Overview - In 2024, Shandong's GDP reached 98,565.8 billion yuan, growing by 5.7% year-on-year, with the primary, secondary, and tertiary industries contributing 6.7%, 40.2%, and 53.1% respectively [2] - The province's listed companies are crucial for economic development, focusing on green, low-carbon, and high-quality growth while enhancing technological innovation [2] Performance of Listed Companies - Shandong's listed companies achieved a total revenue of 2.95 trillion yuan in 2024, a year-on-year increase of 4.61%, while net profit was 175.9 billion yuan, down 3.20% [4] - 78.96% of the companies reported profits, which is 5.27 percentage points higher than the national average, indicating better performance despite challenges in traditional industries [4][5] Contribution to Economic Growth - Listed companies in Shandong contributed 29.92% of the province's GDP, with an added value of 705.18 billion yuan, reflecting their significant role in regional economic growth [5] - The labor productivity of listed companies was 483,600 yuan per person, 2.78 times the national average, showcasing their efficiency [5] Innovation and Growth of SMEs - In 2024, 67 companies on the Growth Enterprise Market reported revenues of 177.98 billion yuan, up 15.13%, and net profits of 11.74 billion yuan, up 49.42%, indicating strong growth in innovative SMEs [6] - The total R&D expenditure for these companies was 6.44 billion yuan, a 8.11% increase, highlighting their commitment to innovation [6] Market Capitalization and Value Management - By the end of 2024, the market capitalization of Shandong's listed companies reached 3.63 trillion yuan, a 4.18% increase, ranking seventh nationally [8] - 125 companies conducted share buybacks, totaling 9.568 billion yuan, reflecting a strong commitment to value management [8] Characteristics of Listed Companies - Private listed companies in Shandong accounted for 62.14% of the total, achieving revenues of 838.06 billion yuan, up 4.64%, and net profits of 431.87 billion yuan, up 16.49% [9][10] - Companies with overseas business generated 842.85 billion yuan in foreign income, a year-on-year increase of 8.89%, indicating the importance of international markets [12] Mergers and Acquisitions - In 2024, 13 listed companies in Shandong participated in mergers and acquisitions, with a total transaction value of 38.75 billion yuan, a 3.58-fold increase [14][15] - The trend of state-owned enterprises merging with peers is becoming more common, enhancing market competitiveness [15] Sustainable Development and ESG - Shandong's listed companies showed a 44.34% ESG report disclosure rate, slightly above the national average, indicating a growing recognition of sustainability [16][17] - The average ESG score for Shandong's companies was 5.79, higher than the national average, with two companies scoring above 9.00 [17] Innovation and Digital Transformation - R&D expenses for Shandong's listed companies reached 84.51 billion yuan, a 3.94% increase, with a focus on enhancing innovation capabilities [18] - The digital economy's core companies reported revenues of 330.38 billion yuan, up 27.57%, demonstrating significant growth in this sector [20] Traditional Industry Transformation - Traditional industries in Shandong are undergoing digital and intelligent transformations, with companies like Shandong High-Speed adopting advanced technologies to enhance operational efficiency [23] - The integration of digital and green technologies is seen as essential for fostering new productive forces in traditional sectors [24]

Core Viewpoint - The increase in terminated agreements for equity transfers in the A-share market is attributed to stricter regulatory scrutiny and market volatility affecting the parties involved [1][2][4]. Group 1: Termination of Agreements - As of May 26, 2023, 25 companies have announced the termination of equity transfer agreements this year, matching the total for the entire previous year [1][2]. - In May alone, 13 companies announced the termination of agreements, with 10 involving controlling shareholders or actual controllers [1][2]. - The majority of these terminated agreements were signed after the implementation of the new reduction regulations in May 2022, with 80% occurring in the fourth quarter of last year [2][3]. Group 2: Reasons for Termination - The reasons for the termination of agreements include stricter regulatory oversight, insufficient funds from the transferee, and fluctuations in secondary market prices leading to breaches of contract [1][2][5]. - Many of the terminated agreements had not received confirmation from the exchange and had not completed the necessary transfer registration procedures [2][3]. Group 3: Regulatory Challenges - The difficulty in regulatory oversight stems from the opaque nature of funding sources, as private equity funds and trust plans do not disclose ultimate investors, complicating the verification process [5][6]. - Key regulatory challenges include identifying hidden relationships between transferors and transferees, and the difficulty in detecting off-the-books agreements that circumvent regulations [5][6]. Group 4: Recommendations for Strengthening Regulation - Suggestions for enhancing regulatory oversight include requiring private equity funds to disclose ultimate beneficiaries, establishing dynamic monitoring of transfer agreements, and increasing penalties for violations [6]. - The use of technology, such as AI, to create a database of equity relationships and identify unusual networks among transferees is also recommended [6].

近日，罗欣药业集团股份有限公司（以下简称"公司"）下属子公司山东罗 欣药业集团股份有限公司收到国家药品监督管理局核准签发的布洛芬注射用浓 溶液《药品注册证书》。现将相关情况公告如下： 一、《药品注册证书》主要内容及产品基本信息 证券代码：002793 证券简称：罗欣药业 公告编号：2025-046 罗欣药业集团股份有限公司 关于布洛芬注射用浓溶液获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 药品名称：布洛芬注射用浓溶液 剂型：注射剂 规格：4ml：0.4g 注册分类：化学药品 3 类 药品批准文号：国药准字 H20254221 通知书编号：2025S01425 上市许可持有人：山东罗欣药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 布洛芬属非甾体类抗炎药，具有镇痛、抗炎、解热作用，是一种有效的前列 腺素(PG)合成抑制剂。病原体及其毒素侵袭人体后，产生与释放内热原，使中枢 合成并释放 PG 增多，PG 是一类具有高度生物活性的物质，参与机体 ...

一份从未现身的《股份转让协议》第8.3条约定，将罗欣药业推向资本运作合规性的风暴眼。曾深入参 与罗欣药业借壳上市的"得怡系"，筹划近半年的股权转让突遭终止，而影响该交易终止的重要合同条款 竟从未披露，证券律师直指此举涉嫌虚假陈述。在此之前，罗欣药业就曾有过信息披露不完整的"前 科"。 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-045 罗欣药业集团股份有限公司 关于合计持股 5%以上股东终止协议转让 公司部分股份的公告 公司合计持股 5%以上股东成都得怡欣华股权投资合伙企业（有限合伙）、克 拉玛依市得怡欣华股权投资有限合伙企业、克拉玛依得怡健康产业投资有限合伙 企业、克拉玛依得盛健康产业投资有限合伙企业保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 罗欣药业集团股份有限公司（以下简称"公司"）于近日收到合计持股 5%以 上股东成都得怡欣华股权投资合伙企业（有限合伙）（以下简称"得怡成都"）、 克拉玛依市得怡欣华股权投资有限合伙企业（以下简称"得怡欣华"）、克拉玛依 得怡健康产业投资有限合伙企业（以下简称"得怡健康"）、克拉玛依得盛健康产 业投资有限合伙企业（以下简称"得盛健康"）的《关于协议转让终止事项的告 知函》，现将相关事项说明如下： 二、本次协议转让终止情况 截至本公告披露日，本次协议转让的股份尚未办理过户手续，未发生实质转 让。公司近日收到了合计持股 5%以上 ...